Linagliptin-metformin oral tablet is available as a brand-name drug. It’s not available as a generic drug. Brand name: Jentadueto. Linagliptin-metformin comes as an immediate-release oral tablet and ...

San Diego, CA - Linagliptin (Tradjenta, Boehringer Ingelheim) shows similar efficacy to glimepiride (Amaryl, Sanofi-Aventis) for the treatment of patients with type 2 diabetes, in terms of controlling ...

Sulfonylureas are often added to metformin to improve glycemic control, but at the known risk of increasing hypoglycemia and weight gain. In a report published in the Lancet, more than 1,500 patients ...

RIDGEFIELD, Conn. and INDIANAPOLIS, Oct. 2, 2012 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE: LLY) today announce data from three pooled analyses for ...

Review the side-effects of Linagliptin as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of the ...

Discover comprehensive details about Linagliptin, including its pronunciation, uses, dosage instructions, indications, and guidelines on how and when to take it or avoid it. The updated prescription ...

Boehringer Ingelheim announced results from its Phase 3 studies of linagliptin for the treatment of type 2 diabetes. In the first study, linagliptin as monotherapy was administered to type 2 diabetes ...

SAN DIEGO, California — Linagliptin appears to have nephroprotective effects when used in the treatment of type 2 diabetes mellitus (T2DM). Maximilian von Eynatten, MD, executive medical director for ...

Boehringer Ingelheim (BI) has released a fistful of data from Phase III clinical trials showing that the DPP-4 inhibitor linagliptin, the most advanced compound in the company’s diabetes portfolio, ...

Senior patient in hospital explaining pain to doctor or nurse Linagliptin is safe for patients with type 2 diabetes and cardiorenal disease. SAN FRANCISCO — Linagliptin is safe for patients with type ...

Tradjenta bottle Boehringer Ingelheim and Lilly announced that the CAROLINA trial met its primary endpoint, demonstrating no increased cardiovascular (CV) risk with linagliptin, a dipeptidyl peptidase ...